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ABSTRACT:  Non-invasive 13C magnetic resonance spectroscopy measurements of the uptake and subsequent metabolism 
of 13C-labeled substrates is a powerful method for studying metabolic fluxes in vivo.  However the technique has been 
hampered by a lack of sensitivity, which has limited both the spatial and temporal resolution.  The introduction of disso-
lution dynamic nuclear polarization in 2003, which by radically enhancing the nuclear spin polarization of 13C nuclei in 
solution can increase their sensitivity to detection by more than 104-fold, has revolutionized the study of metabolism us-
ing magnetic resonance, with temporal and spatial resolutions in the seconds and millimeter ranges respectively.  The 
principle limitation of the technique is the short half-life of the polarization, which at ~20 – 30 s in vivo, limits studies to 
relatively fast metabolic reactions.  Nevertheless, pre-clinical studies with a variety of different substrates have demon-
strated the potential of the method to provide new insights into tissue metabolism and have paved the way for the first 
clinical trial of the technique in prostate cancer. The technique now stands on the threshold of more general clinical 
translation.  I consider here what the clinical applications might be, which are the substrates that most likely will be used, 
how will we analyze the resulting kinetic data and how we might further increase the levels of polarization and extend 
polarization lifetime. 
INTRODUCTION 
The abundance of tissue water protons and the sensitiv-
ity of the proton to NMR detection has allowed imaging 
of tissue anatomy at relatively high resolution, with image 
resolutions in preclinical studies at high magnetic fields 
in the 10 – 100 μm range 1.  Cell metabolites, on the other 
hand, are present at ~10,000x lower concentration than 
tissue water and therefore it is not possible to image them 
at clinical magnetic field strengths, except at relatively 
low spatial (1 cm3) and temporal resolutions (5 - 10 
minutes) 2.  Moreover single 1H spectra, or 1H spectro-
scopic images of tissue metabolites, provide only a profile 
of the steady state metabolite concentrations and lack 
dynamic information about metabolic fluxes.   These can 
be measured in 13C and 1H spectra by the introduction of 
isotopically labeled substrates 3,4.    The use of 13C-labelled 
substrates to investigate metabolic fluxes began in the 
1970s with studies in E. coli and yeast 5,6 and progressed 
subsequently to human studies 3.  The technique can be 
used to follow which metabolites are labeled, and also 
which positions in these molecules are labeled.  The in-
formation content can be enhanced by introducing two 
13C-labeled substrates and then monitoring multiple label-
ing of individual cell metabolites through spin-spin cou-
pling of adjacent 13C labels, which can yield information 
about the relative fluxes through various metabolic path-
ways 7.  Recent and elegant examples of the application of 
this approach include studies on glucose, glutamine and 
acetate metabolism in tumors 8,9.  Although the sensitivity 
of 13C label detection can be enhanced by indirect detec-
tion via spin-coupled protons 10,11 this is still not sufficient 
to enable imaging.  The breakthrough for the field came 
with the demonstration that dissolution dynamic nuclear 
polarization (dDNP) of 13C-labelled cell substrates can 
increase their sensitivity to detection by more than 
10,000x 12.  This has made possible not only imaging of 
hyperpolarized 13C-labelled cell substrates, following in-
travenous injection, but more importantly, the kinetics of 
their conversion into cell metabolites, with spatial resolu-
tions of 2 – 5 mm and temporal resolutions in the sub 
second range 13.  The Achilles heel of the technique, how-
ever, is the relatively short half – life of the polarization in 
vivo, which is typically 20 – 30 s.  This limits the number 
of reactions that can be monitored in vivo to those that 
show fast reaction kinetics.   These will usually be cata-
bolic reactions responsible for energy generation rather 
than the generally slower anabolic reactions involved in 
cell biosyntheses.  The limited lifetime of the polarization 
also restricts the number of sequential enzyme catalyzed 
steps through which a 13C label can be followed, although 
flux of hyperpolarized 13C label from glucose through all 
10 steps of the glycolytic pathway to lactate has been de-
tected 14-17 and imaged 18 (Figure 1). 
There have been several recent and comprehensive re-
views describing the molecules that have been polarized 
and how they have been used 19-23 and therefore I do not 
intend to provide a full coverage of the field.   Instead I 
will concentrate on those substrates that appear to have 
the greatest potential to be used clinically, or that can be 
used pre-clinically to address questions of fundamental 
 biological importance that cannot easily be answered us-
ing more conventional techniques.  The focus is on appli-
cations in oncology, which reflects my own research in-
terests. 
 
Figure 1.   Imaging tumor metabolism with hyperpolarized 
[U-
13
C, U-
2
H]glucose.   a) Localized spectra acquired from the 
indicated tissues (EL4 and LL2 are implanted tumor models).  
Only the tumors show signal from labeled lactate.  This is 
not because glycolytic flux is slow in these other tissues, but 
unlike tumors they do not accumulate lactate under aerobic 
conditions (i.e. they do not show a “Warburg effect”).  b) 
Vertical scale expansion of the spectrum between 160 and 
220 ppm shows signals from dihydroxyacetone phosphate 
(DHAP), a glycolytic intermediate, and a signal that is pre-
dominantly from 6-phsphogluconate (6PG), an intermediate 
in the pentose phosphate pathway 
24
.  c) There is sufficient 
signal from the hyperpolarized [U-
13
C, U-
2
H]glucose, and the 
lactate formed from it, to image both metabolites.  The lac-
tate signal is concentrated in the tumor, which is visible in 
the 
1
H image (outlined in white).   Adapted from 
18
, with 
permission. 
DYNAMIC NUCLEAR POLARIZATION AND 
TRANSFER TO THE SOLUTION STATE 
 Dynamic nuclear polarization 
The sample to be polarized is mixed with a stable radi-
cal, rapidly frozen to form a glass and then placed in a 
high magnetic field (typically greater than 3 T) and at low 
temperature (~1 K).  This low temperature can readily be 
achieved by boiling-off liquid helium under vacuum.  
Crystallization of the sample, which results in the radical 
concentrating in domains and inhibiting the DNP pro-
cess, can be prevented by using solvents such as glycerol 
or dimethylsulfoxide that promote glass formation. The 
magnetic moment of the electron is 658 times greater 
than that of the proton and at this low temperature and 
high magnetic field reaches near unity polarization.   The 
electron spin polarization is then transferred to the nu-
clear spins by microwave irradiation close to the reso-
nance frequency of the electron spin.  Addition of Gd3+ 
ions can be used to shorten the electron spin longitudinal 
relaxation time, improving the DNP enhancement by 50 – 
100% 25.    Nitroxide and trityl radicals have been used in 
general, although radicals have also been produced en-
dogenously by UV irradiation of the sample 26.   For trans-
fer of the polarization to be effective the EPR spectrum of 
the radical should have a line width that exceeds the 
Larmor frequency of the nuclear spin.  Nitroxides have a 
broad EPR spectrum, which covers the Larmor frequency 
of all nuclear spins, whereas trityls have a narrower spec-
trum and are better for polarizing low gamma nuclei, 
such as 13C, and 15N 21.  There is an optimum radical con-
centration; while high concentrations shorten the polari-
zation build-up time they shorten the T1 of the nuclear 
spin and lower the steady state polarization.  The build-
up time constant can be reduced by using a 13C-labeled 
glassing agent, which increases the rate of spin diffusion 
27.  Spin diffusion is also increased by the high concentra-
tion of the 13C-labeled compound to be polarized.  Polari-
zation can be improved by increasing the magnetic field 
strength or by lowering the temperature, however a 
drawback is that the polarization build-up times may be-
come very long 21.  An alternative and very promising ap-
proach for enhancing the rate of 13C polarization and its 
steady state level is to first polarize protons using the rel-
atively inexpensive TEMPO radical followed by Hart-
mann−Hahn cross polarization to the 13C nuclei.  Using 
this approach solution polarizations in [1-13C]acetate of  
>40% (at 1.2 K and 6.7 T) have been achieved in a build-
up time of 810 s 28. 
 Dissolution 
The key innovation introduced by Ardenkjaer-Larsen, 
Golman and colleagues and which has made possible 
medical imaging with 13C-labelled substrates, is the disso-
lution process, in which the hyperpolarized substrate is 
brought rapidly to room temperature with minimal loss of 
polarization 12.  This is achieved by rapidly flushing the 
sample out of the polarizer magnet using a pressurized 
superheated solvent (180°C, ~10 bar).  In order to mini-
mize relaxation it is important to maintain the sample at 
high magnetic field during the dissolution process and 
also to avoid zero field during the transfer to the imaging 
magnet.  Because of the dilution that takes during the 
dissolution process it is important that the molecule to be 
polarized is soluble at high concentration.  With the re-
quirement for a long polarization lifetime (long T1) this 
puts a further restriction on the molecules that can be 
polarized and used for imaging in vivo. 
The majority of 13C-labelled substrates that have been 
used for metabolic imaging have been hyperpolarized 
using the dDNP technique 23,29.   An alternative method is 
parahydrogen-induced polarization (PHIP) (reviewed in 
30), however, with the exception of succinate 31 it has not 
yet been possible to use this technique to hyperpolarize 
the commonly used 13C-labeled cell substrates.  Recently 
Aime and co-workers showed that the carboxyl carbons of 
pyruvate and acetate can be polarized by PHIP by using 
precursors that contain a hydrogenable functionality 32.  
Polarization was then transferred to the carboxyl carbons 
and the molecules cleaved to generate free pyruvate or 
acetate.  In principle this technique could be extended to 
 other carboxylic acids, further extending the molecules 
that can be polarized using this method. 
Much of the early pre-clinical work used prototype po-
larizers built in the laboratory of Ardenkjaer-Larsen, 
Golman and colleagues or with a commercial derivative 
manufactured by Oxford Instruments (HyperSense).   An 
adapted version of the prototype polarizer, operated in a 
clean room adjacent to the MR scanner room, was used in 
the first clinical trial with hyperpolarized [1-13C]pyruvate 
in prostate cancer patients 33.  Other polarizers operating 
on a similar principle have also been described 34.  More 
recently GE have built a polarizer (SPINlab™) that, with 
the appropriate regulatory approval, could be used for 
clinical studies.  The system comprises a closed-cycle, 
sorption pump-based cryogenic system serviced by a 
cryo-cooler, which can achieve temperatures of ~1K and 
can polarize 4 samples simultaneously, thus to some ex-
tent getting around the problem of long polarization 
build-up times 35.   Recycling the helium avoids the need 
for regular refilling as well as reducing costs.  The sample 
to be polarized and the dissolution fluid are placed, under 
sterile conditions, into a sterile fluid path module that 
plugs into the polarizer.  In the longer term these “sterile 
fluid paths” could be made at a remote facility and 
shipped out to radiology departments, where the polariz-
er is sited immediately adjacent to the MR scanner.  Sub-
sequent polarization, dissolution and removal of the radi-
cal is fully automated and the polarized sterile sample is 
then passed through a contactless quality control system, 
which checks the level of polarization, pH, temperature 
and residual radical concentration, before injection into 
the patient.  The original device operated at 3.35 T and 
produced solid-state polarizations of 35 – 40%.   A later 
version operates at 5 T. 
 
EXTENDING THE POLARIZATION LIFETIME 
Short polarization lifetimes have prompted a search for 
methods that could be used to extend them.  One ap-
proach is to remove intramolecular dipole – dipole inter-
actions between the 13C label and adjacent protons by 
deuteration 18,36. Another has been to exploit long-lived 
states that are accessible in coupled spin systems. 
Two spin-½ nuclei may couple together to form a com-
posite system with total spin =0 or 1 (Figure 2).  If the nu-
clei are in magnetically equivalent environments then the 
singlet and triplet states are eigenstates (energy levels) of 
the system.  The spin-0 state, which has only one compo-
nent and is anti-symmetric under exchange of spins, is 
known as a singlet state and does not give rise to an NMR 
signal, whereas the spin-1 state, which is symmetric, con-
sists of three triplet states that are split by their nuclear 
resonance frequency.  Transitions between the triplet 
states are governed by T1 relaxation processes, whereas 
transitions between the singlet and triplet states occur 
with a time constant denoted TS 
37.  The dominant T1 re-
laxation process for coupled spin ½ nuclei in the solution 
state is due to dipole – dipole interactions.  However, this 
relaxation mechanism is symmetric with respect to spin 
exchange and therefore cannot induce singlet – triplet 
transitions.  For this reason TS can be very much longer 
than T1 and therefore by depositing polarization in the 
singlet state its lifetime can be extended.  For a magneti-
cally inequivalent spin pair, where there is a chemical 
shift difference between them, the singlet – triplet transi-
tions are quenched. Manipulating the magnetic equiva-
lence of a weakly coupled spin pair allows the hyperpolar-
ized signal to be stored in the singlet state of the equiva-
lent system, where exchange symmetry is broken, and 
then later returned to the NMR detectable Zeeman states 
of the inequivalent system, where exchange symmetry is 
imposed.   Starting with an inequivalent two-spin system, 
a precursor state is prepared that can be used to populate 
the singlet state as soon as the two spins are made equiva-
lent during a subsequent storage period.   This precursor 
state can be prepared in several different ways (reviewed 
in 37).   These include application of resonant radiofre-
quency pulses in a high magnetic field to excite the pre-
cursor state, which is then transformed into singlet order 
following transfer to low field; preparation of singlet or-
der in a high magnetic field using a radiofrequency pulse 
sequence; application of an audio-frequency pulse se-
quence in a low magnetic field on a pre-polarized sample; 
and exploitation of chemical reactions that change sym-
metry.  Long-lived states have been created in various 
hyperpolarized molecules however, to date, this appears 
to have been achieved in only two molecules that have 
been used for metabolic imaging in vivo; pyruvate and 
fumarate. 
 
Figure 2.  The triplet and singlet states of a magnetically 
equivalent spin-½ pair a) and the triplet states of a magneti-
cally inequivalent spin-½ pair b). α and β denote the spin 
‘‘up’’ and spin ‘‘down’’ states, respectively.  The inequivalent 
spins, which are weakly coupled, show a difference in chemi-
cal shift,  ω, and a spin-spin coupling constant, J. T1 relaxa-
tion processes connect the triplet states and TS defines the 
lifetime of singlet order. 
A study with [2,3-13C]pyruvate showed that singlet order 
can be generated directly in the dDNP process, without 
resort to the pulse sequences mentioned above 38.  During 
dissolution the high-field eigenstates are adiabatically 
 transformed into the nuclear singlet (|S0⟩ ) and triplet 
(|TM⟩ ) eigenstates in the low magnetic field outside the 
polarizer.   For a weakly coupled spin pair with positive 
gyromagnetic ratio, chemical shift difference and 
spin−spin coupling, the correspondence between the low- 
and high-field states is (see Figure 2): 
  ⟩  S0⟩    ⟩  T0⟩   1) 
2 ⟩   T+1⟩    ⟩   T-1⟩   2) 
Nuclear singlet polarization (pS) corresponds to a mean 
population difference between the singlet and triplet 
states, which neglecting relaxation during transport to 
low field, is given by: 
𝑝𝑆=𝑛𝛼1𝛽2 − (𝑛𝛼1𝛼2 + 𝑛𝛽1𝛼2 + 𝑛𝛽1𝛽2) 3⁄ = −𝑝
2 3⁄  3) 
where n is the population of the indicated spin state.  
The negative sign arises due to an excess population in 
the triplet state, depleting the singlet state.   Therefore for 
30% polarization, there would be 3% negative singlet po-
larization.   Transfer of the sample back to high field, re-
versing the transitions shown in equations 1 – 2, results in 
observable magnetization.  This method for generating 
the singlet state was used to investigate singlet lifetimes 
for [2,3-13C]pyruvate in red blood cell suspensions and in 
vivo 39.   Although TS was longer than T1 at low fields (sev-
eral milliTesla) it was shorter than T1 at high fields and, 
moreover, the TS at low field was not significantly longer 
than the T1 at low field of [1-
13C]pyruvate.  Therefore, in 
the case of pyruvate there are relaxation mechanisms that 
have a strong effect on singlet relaxation and there is no 
benefit in generating the singlet state.  Nevertheless, ob-
servation of singlet polarization in pyruvate was demon-
strated in vivo following injection of hyperpolarized [2,3-
13C]pyruvate into mice 39. 
Clearly this method of generating singlet polarization is 
very dependent on the level of polarization that can be 
achieved.  For a polarization of 90%, which can readily be 
obtained for 1H at 6.7 T and 1.2 K 28, and which can be 
transferred to 13C through cross polarization, the 1H sin-
glet polarization would be 27%.   Creating long-lived po-
larization in 1H, as opposed to 13C, has several benefits.  
The 1H gyromagnetic ratio is four-fold greater and there-
fore the sensitivity of detection is higher and the imaging 
gradient strengths required to achieve the same spatial 
resolution are four-fold lower.  In a clinical context, de-
tection of 1H means that it is not necessary to equip the 
scanner with 13C spectroscopic capability.   Bornet et al 40 
polarized the protons in fumarate and generated singlet 
order directly.  In the polarizer, where the sample is fro-
zen, the protons are magnetically inequivalent, however 
following dissolution, when they become magnetically 
equivalent and exchange symmetry is broken, the singlet 
state becomes populated.  Fumarate, with polarization 
stored in the singlet state, was added to fumarase, which 
catalyzes the hydration of fumarate to produce malate.   
At high magnetic field the two protons in malate become 
magnetically inequivalent and the singlet polarization in 
malate is released into observable magnetization.  The TS 
for the fumarate protons at high field was ~60 s, which is 
sufficiently long to make this experiment feasible in vivo.   
However, the experiment was conducted in a Tris-
buffered saline solution in D2O, where a deuteron was 
incorporated into the resulting malate.   The TS in H2O-
containing solutions and in more physiologically relevant 
media, for example in blood, may be much shorter.   The 
benefit of creating this long-lived state in fumarate is that 
the polarization would be largely preserved following dis-
solution, injection and transport in the blood stream to 
the tissue of interest, where the polarization in the singlet 
state would then be released into observable magnetiza-
tion following enzymatic conversion of fumarate into 
malate. 
Although the creation of long-lived states has yet to be 
used to extend the polarization lifetime in vivo of a mole-
cule that would be useful for imaging metabolism it is 
nevertheless potentially a very important methodology 
that may go some way to addressing the fundamental 
limitation of the dDNP technique.  A better understand-
ing of the relaxation mechanisms responsible for singlet 
to triplet conversion may help in identifying molecules 
that would benefit from this approach 37. 
SUBSTRATES USED FOR METABOLIC 
IMAGING 
 Pyruvate 
 [1-13C]Pyruvate has been the most widely used substrate 
to date and has been the first to transition to the clinic 33.  
Following delivery via the circulation the molecule is rap-
idly transported into cells on the monocarboxylate trans-
porters (MCTs), where flux of 13C label into the endoge-
nous lactate and alanine pools is catalyzed by lactate de-
hydrogenase (LDH) and alanine aminotransferase respec-
tively.  Sequential spectra acquired from a tumor, follow-
ing intravenous injection of hyperpolarized [1-
13C]pyruvate, show a decaying signal due to loss of the 
hyperpolarization through spin-lattice relaxation (the T1 
for the carboxyl carbon of pyruvate in vivo is ~30 s) and 
initially an increasing signal from lactate, due to incorpo-
ration of 13C label, followed by T1 relaxation-dependent 
decay (see Figure 3).  Flux of hyperpolarized 13C label from 
injected pyruvate into the endogenous lactate pool has 
been used to grade prostate tumors, more aggressive tu-
mors showed more lactate labeling 41, and to detect early 
responses to drug treatment 42, where in general lactate 
labeling is decreased in responding tumors 23.  In the first 
clinical trial in prostate cancer, lactate labeling was ob-
served in a region of the gland that showed no detectable 
tumor in T2- or diffusion-weighted 
1H MRI, but which 
subsequent histological analysis showed contained dis-
ease 33. 
  
Figure 3.   Exchange of hyperpolarized 
13
C label between 
hyperpolarized [1-
13
C]pyruvate and the endogenous lactate 
pool in a tumor cell suspension.   a) The  [1-
13
C]lactate signal 
at 183 ppm shows an initial increase, due to flux of hyperpo-
larized 
13
C label from [1-
13
C]pyruvate, followed by subsequent 
decay due to T1-dependent relaxation of the polarization.  
The signal at 206 ppm is from natural abundance [2-
13
C]pyruvate, which is a doublet due to coupling with 
13
C at 
the C1 position and which decreases due to the loss of polari-
zation.   b) The pyruvate and lactate peak intensities were fit 
to the modified Bloch equations for two site exchange in 
order to determine a first order rate constant describing flux 
of 
13
C label from pyruvate to lactate (kP) (in the interests of 
clarity the pyruvate peak intensity has been reduced by a 
factor of 100).   The modified Bloch equations for two-site 
exchange are:  
   kL 
L    P    
 kP 
  
dLz
dt
= -rL (Lz - L¥)+ kPPz- kLLz 
  
dPz
dt
= -rP (Pz -P¥)+ kLLz- kPPz 
where Lz and Pz are the z magnetizations of the 
13
C nucleus 
in the lactate and pyruvate carboxyl carbons, L and P are 
the spin lattice relaxation rates (1/T1L,P), and L∞  and P∞ are 
the equilibrium magnetizations (i.e. at t = ∞), which are ef-
fectively equivalent to their concentrations.  Adapted from 
42
, 
with permission. 
Lactate labeling could result from both exchange of the 
hyperpolarized 13C label between the injected hyperpolar-
ized [1-13C]pyruvate and the endogenous lactate pool and 
by net conversion of pyruvate into lactate.  There is con-
siderable evidence for a significant exchange contribution 
19.  In early studies on cells addition of exogenous lactate 
increased the rate of lactate labeling 42.  This is incompat-
ible with net flux, since the added lactate will inhibit for-
ward flux through product inhibition of the enzyme 43, 
but is consistent with exchange, since it increases the 
near-equilibrium NADH concentration, which is limiting 
for the exchange reaction.  This is illustrated in Figure 4, 
which shows the theoretical isotope exchange flux under 
equilibrium conditions and under conditions where the 
NADH concentration is fixed.  Fitting the calculated iso-
tope exchange fluxes under the former conditions to the 
Michaelis - Menten equation gives an apparent Km of 
LDH for pyruvate of 13 μM, whereas the true Km is 125 
μM. This low apparent Km is due to a decrease in the 
equilibrium NADH concentration as the concentration of 
pyruvate is increased. If the NADH concentration in the 
model is fixed at 10 μM then the isotope exchange rate 
increases to much higher levels, reflecting the fact that it 
is limiting for the exchange reaction, and the apparent 
Km for pyruvate is increased to 76 μM.  
 
Figure 4.   Effect of pyruvate concentration on the calculated 
LDH isotope exchange velocity (VLDH). The lower curve (dot-
ted line) was calculated assuming an equilibrium NADH 
concentration.  The upper curve (solid line) was calculated 
by fixing the NADH concentration in the kinetic model at 10 
µM.  The lactate concentration in the model was 10 mM and 
the NAD concentration 0.4 mM.  The curves were calculated 
using the following equation: 
VLDH=
E0
k4k6[H][P]
k5
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where H represents NADH, P represents pyruvate and L rep-
resents lactate.  The equation was derived assuming an or-
dered ternary complex mechanism for the enzyme (see be-
low).  The rate constants were taken from the literature.  
Adapted from 
43
, with permission. 
Subsequent studies showed that addition of exogenous 
lactate also accelerated the observed isotope exchange 
flux in vivo 44.   Exchange was demonstrated directly in 
tumor cell suspensions by adding [3-13C]pyruvate and de-
 tecting the 13C label in the proton spectrum through split-
ting of the methyl proton resonances of lactate and py-
ruvate due to 13C-1H J coupling.  There was no change in 
the total pyruvate concentration but a decrease in the 
concentration of [3-13C]pyruvate and an increase in the 
concentration [3-12C]pyruvate, again demonstrating ex-
change of 13C label between pyruvate and lactate 42.  More 
recently, in experiments with hyperpolarized [1-
13C]pyruvate in glioblastoma cells, mass spectrometric 
measurements on cells to which an equivalent concentra-
tion of non-polarized [3-13C]pyruvate had been added 
showed there was no increase in the total lactate pool size 
over the time course of the hyperpolarized experiment, 
again demonstrating that the observed lactate 13C-labeling 
was due to exchange rather than net flux 45.  Exchange 
was demonstrated directly in tumors in vivo using a mag-
netization transfer experiment 46.  Saturation of the hy-
perpolarized [1-13C]pyruvate resonance resulted in an ac-
celerated decay of the hyperpolarized [1-13C]lactate reso-
nance, demonstrating that there must have been flux of 
hyperpolarized 13C magnetization from lactate to py-
ruvate.   That the observed label flux is due predominant-
ly to an LDH-catalyzed exchange reaction has important 
implications for the interpretation of this experiment.  
LDH has an ordered ternary complex mechanism, where 
the coenzymes NAD+ and NADH bind first and then lac-
tate and pyruvate respectively. 
E + NAD+
k 2
¬ ¾¾
k1
¾ ®¾
E.NAD+
E.NAD+ + Lac
k 4
¬ ¾¾
k 3
¾ ®¾
E.NADH +Pyr
E.NADH
k 6
¬ ¾¾
k 5
¾ ®¾
E + NADH
 
Exchange of isotope label between lactate and pyruvate 
can be much faster than between NAD+ and NADH and 
faster therefore than the next chemical flux catalyzed by 
enzyme i.e. the metabolically relevant net conversion of 
pyruvate and NADH to lactate and NAD+ 19. 
Several kinetic models have been used to analyze ex-
change of hyperpolarized 13C label between injected [1-
13C]pyruvate and the endogenous lactate pool.  The first 
used fitting of the pyruvate and lactate signal intensities 
to the modified Bloch equations for two-site exchange 
and ignored the effects of pyruvate delivery 42 (Figure 3).    
A recent comparison with more complex models conclud-
ed that this simple two-site exchange model, and even 
simpler unidirectional models, are sufficient to estimate 
the first order rate constant, kP, describing label flux be-
tween pyruvate and lactate 45.  Another approach, which 
does not require curve fitting, is to take the ratio of the 
areas under the lactate and pyruvate signal intensity 
curves, which was shown to be proportional to kP 
47.  An 
added advantage of this analysis was that it was found to 
be independent of the pyruvate arterial input function 
(AIF), although direct measurements of the pyruvate AIF 
have shown that it has little influence on estimates of kP 
48.  However, while estimates of kP appear to be robust, 
the key problem is that without an estimate of pyruvate 
concentration in the tissue we are unable to determine a 
metabolically relevant value for the isotope flux.  While 
measuring a first order rate constant and changes in this 
rate constant with various interventions may be adequate 
in preclinical animal studies, where the tissues are effec-
tively identical and the pyruvate concentration delivered 
to the tissue may be very reproducible, this may be more 
of a problem in the clinic.  Although absolute measure-
ments of flux in the clinic may be difficult it may be suffi-
cient simply to measure changes in the rate constant be-
fore and after an intervention, for example tumor treat-
ment. 
Analyzing exchange data using the modified Bloch 
equations for two-site exchange, or variants of these 
equations, assumes that there is no loss of polarization in 
enzyme-substrate complexes, for example in the 
LDH.NAD+.Lactate and LDH.NADH.Pyruvate ternary 
complexes.   The concentrations of these enzyme-
substrate complexes are small when compared with the 
free substrate concentrations and consequently they are 
turning over so rapidly that their lifetimes are short when 
compared with the polarization lifetime. Therefore there 
is little opportunity for loss of polarization 49.  This will be 
the case even if the polarization lifetime is shortened in 
an on-enzyme complex. 
Studies on the dependence of the exchange rate on py-
ruvate concentration in isolated cells 43,50 and in vivo 51 
implied that the exchange velocity must depend on MCT 
as well as LDH activity.  The observed apparent Km was 
similar to that for pyruvate transport, and much higher 
than the Km of LDH for pyruvate in the exchange reac-
tion 43 (see Figure 4).  More recent studies have demon-
strated the importance of MCT activity for the exchange.  
In breast cancer (MCF7) cells treated with a mitogen-
activated protein kinase inhibitor there was a 31% de-
crease in label flux whereas in prostate cancer (PC3) cells 
there was a 167% increase.  LDH expression and lactate 
concentration were increased in both cell lines following 
drug treatment.   The decrease in exchange in the MCF7 
cells was explained by a decrease in MCT1 expression that 
was not observed in the PC3 cells 52.   In a bioreactor study 
with perifused metastatic and non-metastatic renal carci-
noma cells the metastatic cells showed an apparently 
lower rate of lactate labeling.  This was explained by high-
er expression of MCT1 in the metastatic cells, which led to 
more rapid export of labeled lactate and loss from the 
sensitive region of the NMR coil 53.  Application of meta-
bolic control analysis showed that in murine lymphoma 
cells control of isotope flux was shared nearly equally be-
tween the membrane transporters and LDH 43.  A similar 
analysis could potentially be performed in vivo by using 
PI3K inhibitors to selectively lower the expression of LDH 
and then determining the effects on the exchange rate 
43,54.   Another approach would be to use diffusion 
weighting to localize the pyruvate and lactate signals to 
the intra- and extracellular spaces and thus to examine 
the effects of transport more directly.  In the murine lym-
 phoma model, diffusion measurements in vivo showed 
that most of the labeled lactate formed from hyperpolar-
ized [1-13C]pyruvate was intracellular over the time-course 
of the experiment 55.    In a diffusion-weighted spin echo 
experiment with hyperpolarized [1-13C]lactate there was a 
progressive increase in signal intensity, which measure-
ments in the presence of an MCT inhibitor showed was 
due in small part to tumor cell uptake and in larger part 
to extravasation of the labeled lactate. 
Measurements of hyperpolarized 13C label exchange be-
tween injected pyruvate and endogenous lactate are ideal-
ly suited to tumor imaging since the lactate pool size is 
often large, due to the high levels of aerobic glycolysis 
displayed by tumors (the “Warburg effect”) 56,57, and the 
high levels of expression of the MCTs and LDH.  The 
highly interconnected nature of metabolic pathways, 
which form “scale free” networks, means that this isotope 
flux is likely to be affected by disparate interventions that 
affect any part of the metabolic network 58 and probably 
explains why nearly all studies have reported some effect 
of tumor treatment on this flux 23.  A corollary is that in 
order to understand what the observed changes in flux 
mean it is important to have a thorough understanding of 
the underlying mechanism.  For example, whereas an 
MCT inhibitor might be expected to decrease the ex-
change through inhibition of pyruvate uptake, this might 
be offset if the inhibitor also leads to an increase in the 
steady state endogenous lactate concentration.  Which 
effect predominates will depend on the relative flux con-
trol coefficients of the MCTs and LDH for the exchange, 
which are likely to vary between different tumor types. 
Treatment response is usually detected in the clinic by 
looking for evidence of reductions in tumor size using 
anatomical imaging with CT or MRI.  However, these 
morphological changes may take weeks or even months 
to become apparent and may not happen at all with cyto-
static therapies 59.   Imaging changes in metabolism can 
give a much earlier indication of whether a drug is engag-
ing with its target, enabling ineffective treatments to be 
abandoned and providing an opportunity to try alterna-
tives earlier during the course of the disease 59.  PET 
measurements with the glucose analog, 
18Fluorodeoxyglucose (FDG), and its increased uptake by 
tumors, are already widely used in the clinic to detect and 
grade tumors and to monitor their response to treatment 
59.  Since the FDG-PET and hyperpolarized [1-13C]pyruvate 
experiment have been shown to be similarly sensitive for 
detecting early evidence of treatment response in a mu-
rine lymphoma model 60 it is pertinent to ask what ad-
vantages the hyperpolarized [1-13C]pyruvate experiment 
might have over the FDG-PET experiment in the clinic.   
The hyperpolarized [1-13C]pyruvate experiment could be 
used multiple times in an iterative approach to select the 
best drug or drug combination to treat an individual pa-
tient, whereas with FDG-PET the exposure to ionizing 
radiation may limit the number of times that a patient 
could be imaged.   Another advantage of imaging with 
hyperpolarized [1-13C]pyruvate is that it can be used in 
tumors where PET imaging of FDG uptake is problematic, 
for example in brain tumors, where high levels of FDG 
uptake in surrounding brain tissue can make detection of 
tumor uptake difficult and in the prostate, where low up-
take in prostate tumors can be masked by high signal 
from the adjacent bladder 59.  The disadvantage of imag-
ing with hyperpolarized [1-13C]pyruvate is that the short 
lifetime of the polarization prevents extensive imaging 
beyond the immediate vicinity of the primary tumor, 
whereas the sensitivity of FDG-PET combined with 
whole-body imaging makes it a very effective tool for de-
tecting distant metastases 61.  Another disadvantage of the 
hyperpolarized pyruvate experiment is that it requires 
injection of supra-physiological pyruvate concentrations.  
For example, the normal concentration of pyruvate in 
human blood is ~50 μM 62, whereas in the clinical trial in 
prostate cancer hyperpolarized [1-13C]pyruvate was inject-
ed at a plasma concentration of  ~1.5 mM 33.  Although 
there was no evidence of toxicity it would clearly be desir-
able to inject the labeled molecule at more physiological 
concentrations.  Since the observed label flux is due pre-
dominantly to an exchange reaction and lactate is present 
in human blood at concentrations of 1 – 5 mM this could 
be achieved by injecting hyperpolarized [1-13C]lactate in-
stead of pyruvate and observing labeling in the endoge-
nous pyruvate pool.  However, this experiment gives 
much less signal because the pyruvate pool is very small 
when compared to the lactate pool 62.  An alternative is to 
observe exchange of deuterium label between injected 
hyperpolarized [2-2H, 1-13C]lactate and the endogenous 
lactate pool, where the deuterium label is detected via the 
spin-coupled hyperpolarized 13C label in a heteronuclear 
spin echo experiment (see Figure 5) 62.  The phase of the 
echo indicates whether the observed hyperpolarized [1-
13C]lactate is protonated at the C-2 position and the am-
plitude of the echo, when compared to the signal ob-
tained after the first low flip angle pulse in the sequence, 
can potentially indicate the location of the labeled lactate, 
particularly if the sequence is diffusion-weighted.  When 
this experiment was performed in a murine lymphoma 
model there was a progressive increase in the echo ampli-
tude due mainly to extravasation of the labeled lactate 
and in part to tumor cell uptake.   As well as dispensing 
with the need for an unphysiologically high pyruvate con-
centration this experiment, which interrogates the same 
biochemistry as the pyruvate experiment, also simplifies 
imaging since there is no change in chemical shift.  The 
lactate labeling is determined simply from the phase of 
the single observed 13C resonance. 
  
Figure 5. Assessing lactate dehydrogenase activity by meas-
uring hydrogen/deuterium exchange in hyperpolarized L-[1-
13
C,U-
2
H]lactate.  a) Scheme showing exchange of the C2 
deuterium label in hyperpolarized L-[1-
13
C,U-
2
H]lactate for 
protons from the endogenous NADH pool and, ultimately, 
from the endogenous lactate pool.    Application of a 
1
H 180° 
pulse in a heteronuclear spin echo experiment (with τ = 1/J; 
~310 ms) results in phase inversion of the hyperpolarized 
13
C 
signal from lactate that has a proton at the C2 position.  
Adapted from 
62
, with permission. 
Although imaging is likely to continue to play an im-
portant role in monitoring the responses of tumors to 
treatment in the clinic it now seems likely that it will be 
used alongside other non-invasive methods for assess-
ment of treatment response.  An important new devel-
opment in this regard has been the analysis of circulating 
tumor DNA (ctDNA) in the plasma, which was shown to 
be capable of detecting response in breast tumors before 
there were any changes in tumor size, determined by 
conventional morphological imaging 63.  Sequencing of 
ctDNA has also been used to monitor the evolution of 
treatment resistance 64.  This is a powerful new technolo-
gy that needs to be evaluated in comparison with func-
tional imaging methods, such as the metabolic imaging 
methods described here, which can give a much earlier 
indication of treatment response. 
In tissues with high mitochondrial activity, such as 
heart muscle, [1-13C]pyruvate is decarboxylated in the re-
action catalyzed by pyruvate dehydrogenase (PDH) to 
produce 13CO2.  The labeled CO2 is in exchange with bi-
carbonate and at physiological pHs most of this labeled 
CO2 will be observed as H
13CO3
–.  In systems where there 
is sufficient carbonic anhydrase activity and the 13CO2 and 
H13CO3
– pools reach isotopic equilibrium the 
13CO2/H
13CO3
– signal ratio can be used to estimate pH 65,66.   
In perfused hearts PDH flux was shown to be modulated 
by the availability of fatty acids 67 and in vivo by fasting 
and diabetes 68.  Temporary coronary occlusion in the pig 
heart in vivo led to a loss of H13CO3
– production, indicat-
ing a decrease in PDH activity, despite restoration of per-
fusion, as indicated by contrast agent enhanced MRI and 
by the delivery of pyruvate and subsequent labeling of 
alanine and lactate 69.  Further studies suggest that these 
experiments with [1-13C]pyruvate in the heart should 
translate to the clinic 70.   Hyperpolarized [2-13C]pyruvate 
resulted in labeling of [1-13C]-acetylcarnitine, [5-13C]citrate 
and [5-13C]glutamate in the perfused heart, which was 
decreased following ischemia and reperfusion 71.  Howev-
er, this labeled form of pyruvate is unlikely to translate to 
the clinic due to the low signal intensities of its labeled 
metabolites.  The primary fate of hyperpolarized  [1-
13C]pyruvate in the perfused liver was shown to be car-
boxylation, rather than oxidation by PDH, which resulted 
in labeling of malate and aspartate.  The H13CO3
– that was 
observed was produced via the gluconeogenic enzyme, 
phosphoenolpyruvate carboxykinase 72.  However, in the 
liver in vivo production of H13CO3
– seems to be predomi-
nantly via PDH 23. 
 Fumarate 
The primary aim of cancer treatment is to selectively 
kill tumor cells.  Hyperpolarized [1-13C]pyruvate has the 
potential to show whether a drug has hit its target in a 
tumor; hyperpolarized [1,4-13C]fumarate can show wheth-
er there is subsequent cell death.  Fumarate uptake by 
cells is slow on the timescale of the polarization.  Howev-
er, when a cell dies and becomes necrotic and the plasma 
membrane becomes leaky, fumarate can enter the cell 
rapidly, or the enzyme fumarase can leak out, and 
fumarase can then catalyze the rapid hydration of 
fumarate to produce malate.  Detection of malate, follow-
ing injection of hyperpolarized [1,4-13C]fumarate, appears 
to be a sensitive indicator of necrotic cell death 73, detect-
ing relatively low levels of diffuse cell death 74.  This sub-
strate is also likely to translate to the clinic, where it 
could be used to detect cell death in tumors post treat-
ment, and potentially also in other tissues where disease 
is present 75. 
 Glucose 
PET measurements of FDG uptake interrogates just 
three steps in carbohydrate metabolism; delivery via the 
bloodstream, cell uptake on the glucose transporters and 
subsequent phosphorylation and trapping in the reaction 
catalyzed by hexokinase.  Both the glucose transporters 
and hexokinase activity are frequently up-regulated in 
tumors.   Measurements with polarized [1-13C]pyruvate 
also interrogates just three steps; delivery via the circula-
tion, cell uptake on the monocarboxylate transporters and 
subsequent isotope exchange in the reaction catalyzed by 
 LDH.  In tumors expression of LDH and the monocarbox-
ylate transporters is also often increased.  Combining 
these two experiments using a PET/MR machine has the 
potential to examine flux in the entire glycolytic pathway.  
This can also be achieved by using hyperpolarized [U-13C, 
U-2H] glucose.  Deuteration increases the T1s of the glu-
cose carbons from <1 s to ~10 s and has allowed measure-
ments of label flux from glucose to lactate.  Measure-
ments with hyperpolarized [U-13C, U-2H] glucose have 
been made in E. coli 14, yeast 15 and tumor cells in vitro 16,17 
and have also been performed in a tumor model in vivo 18, 
where flux was decreased following drug treatment.   As 
well as signal from lactate, signals from glycolytic inter-
mediates and a pentose phosphate pathway intermediate, 
6-phosphogluconate, were also observed 24 (Figure 1).  The 
latter offers the possibility of real time flux measurements 
in a pathway that is responsible, through the generation 
of NADPH, for resistance to oxidative stress and which is 
associated with tumor aggressiveness and resistance to 
treatment.   Although hyperpolarized [U-13C, U-2H] glu-
cose can provide unique information about real time 
pathway fluxes, the short half-life of the polarization will 
make it challenging to translate to the clinic, unless ways 
can be found to deliver the labeled glucose more rapidly 
to the tissue of interest. 
 
 Ascorbate and Dehydroascorbate 
Ascorbate (AA) buffers reactive oxygen species (ROS), 
such as superoxide and hydrogen peroxide, by reducing 
them and in the process is oxidized to dehydroascorbic 
acid (DHA).  Extracellular DHA is transported into cells 
on the glucose transporters where it is reduced to AA.  
The C-1 labeled molecules have long T1s and polarize well 
76,77.   Despite tumors having a high ROS load, injection of 
hyperpolarized [1-13C]AA into tumor-bearing mice result-
ed in no detectable oxidation in the tumor 76.  However, 
injection of [1-13C]DHA into tumor-bearing animals re-
sulted in rapid reduction of DHA to AA in the tumors 76,77, 
and also in other tissues including kidneys, liver, brain 78.  
This may partly explain why very little tumor oxidation of 
AA was observed.  The rate of DHA reduction may report 
on the capacity of the tumor cell to resist oxidative stress.    
However, DHA results in transient respiratory suppres-
sion and therefore it is unlikely that this substrate will 
translate to the clinic. 
IMAGING 
The polarization is non-recoverable and therefore effi-
cient use must be made of it in generating an image.  
Moreover, for molecules like pyruvate, where the useful 
information is in the kinetics of exchange, and for mole-
cules like fumarate, where we cannot know a priori when 
the maximum malate signal will be observed, it is desira-
ble to collect a series of rapidly acquired images.  Various 
pulse sequences have been developed that satisfy these 
requirements and are expected to produce image resolu-
tions in the clinic of ~5 mm (reviewed in 21).  Spiral chem-
ical shift imaging, in which spiral readout gradients sam-
ple the x and y dimensions simultaneously and in which 
the spiral gradients are concatenated multiple times for 
chemical shift encoding, can be used to generate 2D spec-
troscopic images of a single slice in less than a second 13.  
An iterative least squares chemical shift based method, 
which requires prior information about the chemical 
shifts of the labeled compounds and that takes advantage 
of the sparsity of the hyperpolarized 13C spectrum, can be 
used to minimize the number of excitations required for 
spectral decomposition 79.  Echo planar spectroscopic 
imaging sequences and compressed sensing have also 
been used to accelerate image acquisition 80.  An alterna-
tive to spectroscopically resolving the labeled metabolites 
is to excite each one individually using spectral – spatial 
pulses 81.  Multi-band spectral – spatial pulses can be used 
to minimally excite the injected labeled substrate, with a 
low flip angle, preserving the reservoir of polarization in 
the tissue, while exciting the less intense resonances from 
the labeled metabolites produced from it with larger flip 
angle pulses 80.  
Tumor heterogeneity has been correlated with thera-
peutic resistance and subsequent relapse 82 and clearly 
imaging heterogeneity with hyperpolarized 13C-labelled 
substrates would be of considerable interest.  For exam-
ple, different clones in a tumor that express different on-
cogenes may present distinct metabolic signatures that 
could be imaged.  However, in some cases imaging within 
the tumor may be unnecessary and it may be sufficient to 
know only that the signal arises from the tumor itself.  
For example, since fumarate is a positive contrast agent, 
which detects dead cells through the production of mal-
ate, imaging at low resolution will enhance the detection 
of low levels of diffuse cell death. 
 
CONCLUDING REMARKS 
While hyperpolarized 13C-labelled cell substrates can be 
used to make unique measurements in preclinical studies, 
arguably the true power of this technique lies in its capa-
bility to make these measurements in the clinic.   The 
completion of the first clinical trial in prostate cancer has 
demonstrated that the technique will produce detectable 
signals in tumors; the key question now is will it find an 
important clinical application, which affects clinical deci-
sion-making and changes the way we treat patients.   One 
can speculate in general terms what these applications 
might be.  Pathologies are often characterized by ische-
mia, hypoxia and inflammation, with attendant increases 
in tissue lactate concentration and LDH activities.  There-
fore, in principle, the presence of many diseases, and their 
responses to treatment, could be detected using hyperpo-
larized [1-13C]pyruvate.  The presence of disease is also 
often associated with cell death, for example tumors fre-
quently host high levels of dead cells.  Therefore disease 
and response to treatment should also be detectable with 
hyperpolarized [1,4-13C]fumarate.  FDG has been a com-
mercial and clinical success, because it gives good con-
trast and, unlike many PET tracers, it can be used in many 
different disease settings.  Perhaps pyruvate and fumarate 
will be the equivalent tracers of the dDNP world, applica-
 ble for detection and treatment response monitoring in 
many different diseases. 
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